Nusayba A. Bagegni
YOU?
Author Swipe
View article: Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
HER2 subtype and genomic alterations for all patients
View article: Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplementary Tables 1-7
View article: Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplemental Figure 3. Interaction between HER2-positive status and oncogenic pathways on overall survival.
View article: Data from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Data from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer Open
Purpose:Clinical tools to monitor treatment response and metastatic risk could improve early-stage triple-negative breast cancer (TNBC) care. Although molecular residual disease assays show promise, their use in the neoadjuvant setting req…
View article: Supplementary Data 1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Supplementary Data 1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer Open
Supplementary Figures S1-S5
View article: Supplemental Table S1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer
Supplemental Table S1 from Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer Open
Details of patient-level evaluable samples
View article: Supplementary Data 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplementary Data 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
HER2 subtype and genomic alterations for all patients
View article: Supplemental Figure 3 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 3 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 3. Interaction between HER2-positive status and oncogenic pathways on overall survival.
View article: Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 2. Interaction between HER2-low status and oncogenic pathways on overall survival.
View article: Data from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Data from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Introduction: About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody-drug conjugates (ADC). While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low…
View article: Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 2 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 2. Interaction between HER2-low status and oncogenic pathways on overall survival.
View article: Supplementary Tables 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplementary Tables 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplementary Tables 1-7
View article: Supplementary Tables 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplementary Tables 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplementary Tables 1-7
View article: Supplemental Figure 3 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 3 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 3. Interaction between HER2-positive status and oncogenic pathways on overall survival.
View article: Supplemental Figure 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 1. Mutation distribution for the PIK3CA gene in the overall study population divided by HER2-status.
View article: Supplementary Data 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplementary Data 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
HER2 subtype and genomic alterations for all patients
View article: Supplemental Figure 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer
Supplemental Figure 1 from Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer Open
Supplemental Figure 1. Mutation distribution for the PIK3CA gene in the overall study population divided by HER2-status.
View article: Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
HER2 subtype and genomic alterations for all patients
View article: Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplementary Tables 1-7
View article: Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplemental Figure 1. Mutation distribution for the PIK3CA gene in the overall study population divided by HER2 status.
View article: Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplemental Figure 2. Interaction between HER2-low status and oncogenic pathways on overall survival.
View article: Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplemental Figure 3. Interaction between HER2-positive status and oncogenic pathways on overall survival.
View article: Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplemental Figure 2. Interaction between HER2-low status and oncogenic pathways on overall survival.
View article: Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplemental Figure 3. Interaction between HER2-positive status and oncogenic pathways on overall survival.
View article: Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
HER2 subtype and genomic alterations for all patients
View article: Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplemental Figure 1. Mutation distribution for the PIK3CA gene in the overall study population divided by HER2 status.
View article: Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Supplementary Tables 1-7
View article: Data from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Data from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Purpose:About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody–drug conjugates. While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast canc…
View article: TIPS-19 TRIAL IN PROGRESS: SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON TRASTUZUMAB/PERTUZUMAB OR T-DM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2+ BREAST CANCER WITH THE ADDITION OF TUCATINIB (BRIDGET)
TIPS-19 TRIAL IN PROGRESS: SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON TRASTUZUMAB/PERTUZUMAB OR T-DM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2+ BREAST CANCER WITH THE ADDITION OF TUCATINIB (BRIDGET) Open
Despite trastuzumab-based therapy, up to half of patients with HER2+ metastatic breast cancer (MBC) will develop brain metastases (BrM). First-line therapy for HER2+ MBC, taxane/trastuzumab/pertuzumab (TP), demonstrates poor brain permeabi…
View article: Data from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Data from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer Open
Purpose:About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody–drug conjugates. While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast canc…